EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Morbidity and Mortality of Ondansetron in Patients with Non-congenital Long QT Syndrome: A Review Article

Ali Al-Ramadan, George G Kidess, Abdul Rasheed Bahar, Yasemin Bahar, Mohammad Hazique, MChadi Alraies iD

Cardiovascular Drugs and Therapy · 2026

DOI: 10.1007/s10557-025-07766-2 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cardiovascular Drugs and Therapy, 2026. Verfasst von Ali Al-Ramadan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Wayne State University, Detroit Medical Center, Detroit, MI, USA. Hauptthemen laut MEDLINE: Ondansetron, Long QT Syndrome, Antiemetics, Serotonin 5-HT3 Receptor Antagonists. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Selective 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists are widely used for managing chemotherapy-induced, post-operative, and radiation-induced nausea and vomiting. The 5-HT3 receptor, a ligand-gated ion channel in the nervous system, regulates vomiting and gastrointestinal motility. Selective antagonists like ondansetron, granisetron, and tropisetron treat chemotherapy and post-surgical nausea, while non-selective antagonists include metoclopramide and prochlorperazine. Despite their efficacy, a critical safety concern is the potential for prolonging the QT interval, which can predispose patients to life-threatening arrhythmias such as torsades de pointes, particularly in those with congenital long QT syndrome. This risk has led to FDA dosing recommendations and an emphasis on cardiac monitoring, particularly in patients with predisposing factors such as electrolyte imbalances, cardiac conditions, or concurrent QT-prolonging drugs. This review explores the underlying mechanisms of QT-interval prolongation associated with the selective 5-HT3 receptor antagonist ondansetron, evaluates its impact on morbidity and mortality in at-risk populations, and discusses risk mitigation strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OndansetronLong QT SyndromeAntiemeticsSerotonin 5-HT3 Receptor AntagonistsNauseaHumansRisk FactorsVomitingRisk Assessment

Stichwörter der Autor:innen

5-HT3 receptor antagonistsNon-congenital long QT syndromeOndansetronQT interval prolongationTorsades de pointes

Substanzen

OndansetronAntiemeticsSerotonin 5-HT3 Receptor Antagonists

Autor:innen und Institutionen

  • Department of Medicine, Wayne State University, Detroit Medical Center, Detroit, MI, USA.
  • Wayne State University School of Medicine, Detroit, MI, USA.
  • Wayne State University, Detroit, MI, USA.
  • Nuvance Health/Vassar Brothers Medical Center, Poughkeepsie, NY, USA.
  • Department of Cardiology, Detroit Medical Center, Detroit, MI, USA. alraies@hotmail.com.
  • Cardiovascular Institute, Detroit Medical Center, Wayne State University, DMC Heart Hospital, 311 Mack Ave, Detroit, MI, 48201, USA. alraies@hotmail.com.

ORCID-Profile: MChadi Alraies

Zitieren

APA

Al-Ramadan, A., Kidess, G. G., Bahar, A. R., Bahar, Y., Hazique, M., & Alraies, M. (2026). Morbidity and Mortality of Ondansetron in Patients with Non-congenital Long QT Syndrome: A Review Article. Cardiovascular Drugs and Therapy. https://doi.org/10.1007/s10557-025-07766-2

Vancouver

Al-Ramadan A, Kidess GG, Bahar AR, Bahar Y, Hazique M, Alraies M. Morbidity and Mortality of Ondansetron in Patients with Non-congenital Long QT Syndrome: A Review Article. Cardiovascular Drugs and Therapy. 2026. doi:10.1007/s10557-025-07766-2

BibTeX
@article{AlRamadan2026,
  author = {Al-Ramadan, Ali and Kidess, George G and Bahar, Abdul Rasheed and Bahar, Yasemin and Hazique, Mohammad and Alraies, MChadi},
  title = {Morbidity and Mortality of Ondansetron in Patients with Non-congenital Long QT Syndrome: A Review Article},
  journal = {Cardiovascular Drugs and Therapy},
  year = {2026},
  doi = {10.1007/s10557-025-07766-2}
}
Kostenlos starten →